Ireland
--:--IST
Starting soon Not applicable

27-Inch Versus 55-Inch Monitors in Women Undergoing Endometrial Cancer Surgery

NCT07882277 · tracked via the Priya Life Science Turkey tracker
Sponsor
Metehan Uzundal
Phase
Not applicable
Started
2026-10
Last updated
2026-10-20

Condition(s) studied

Endometrial Cancer

Investigational drug(s) / intervention(s)

27-Inch Endoscopic Imaging Monitor55-Inch Endoscopic Imaging Monitor

27-Inch Endoscopic Imaging Monitor: Use of a 27-inch 4K-2D endoscopic imaging monitor during minimally invasive endometrial cancer surgery.

55-Inch Endoscopic Imaging Monitor: Use of a 55-inch 4K-2D endoscopic imaging monitor during minimally invasive endometrial cancer surgery.

Study summary

This study will compare the use of 27-inch and 55-inch endoscopic imaging monitors during minimally invasive surgery for women with endometrial cancer. Participants will be randomly assigned to one of the two monitor groups. All participants will undergo the same standard surgical procedure; only the monitor size used during surgery will differ. The main question is whether monitor size affects total operative time. The study will also evaluate sentinel lymph node dissection time, blood count changes, complications, infections, hospital stay, and drain-related outcomes during the first 30 days after surgery.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Female patients aged 18 years or older * Histologically diagnosed endometrial cancer with planned surgical treatment * Eligible for minimally invasive surgery * Planned total laparoscopic hysterectomy with bilateral salpingectomy or bilateral salpingo-oophorectomy and sentinel lymph node dissection * No severe systemic disease that would contraindicate laparoscopic surgery based on preoperative evaluation * Standard cervical four-quadrant indocyanine green injection planned for sentinel lymph node mapping * Bilateral sentinel lymph node mapping and bilateral sentinel lymph node dissection feasible during surgery * Preoperative hemoglobin level of 10 g/dL or higher * Able and willing to provide written informed consent Exclusion Criteria: * Distant metastasis detected on preoperative imaging or clinical evaluation * Not suitable for minimally invasive surgery, such as severe cardiopulmonary disease * Conversion from laparoscopy to laparotomy * Failure of bilateral sentinel lymph node mapping or inability to perform bilateral sentinel lymph node dissection * Systematic pelvic and/or para-aortic lymph node dissection performed * Body mass index of 40 kg/m² or higher * Uterine size equivalent to 12 weeks of gestation or larger * Dense bowel or omental adhesions detected intraoperatively * History of abdominal surgery through a midline incision * History of myomectomy * History of tubo-ovarian abscess * History of three or more cesarean deliveries * Need for an additional major surgical procedure outside the standardized surgical protocol * Preoperative hemoglobin level below 10 g/dL * Refusal to participate or inability to provide informed consent

Primary outcome measure(s)

  • Total Operative Time — During surgery
    Total operative time, defined as the time from entry of the laparoscopic optic into the abdomen after trocar placement to completion of surgery, measured in minutes.

Trial sites (1)

FacilityCityRegionStatus
Basaksehir Cam and Sakura City Hospital Istanbul Istanbul
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07882277 on ClinicalTrials.gov ↗ ← All trials in Turkey